Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2013-05-08 Director's Dealing
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
STOCK OPTION GRANT 05/06/2013
Director's Dealing
2013-05-08 English
STOCK OPTION DATED 05/06/2013
Director's Dealing
2013-05-08 English
STOCK OPTION GRANT 05/06/2013
Director's Dealing
2013-05-08 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 29, 2013. It details a private placement transaction involving the issuance and sale of common stock and Series B Convertible Preferred Stock, including terms of the securities, registration obligations, and advisory fees. The content focuses on a financing event and related agreements, such as the Securities Purchase Agreement and Advisory Agreement. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a report of management or board changes, legal proceedings, or voting results. The primary subject is a capital raising transaction and related agreements, which fits the definition of a Capital/Financing Update (CAP). The document length (7514 characters) and detailed description of the financing terms support this classification with high confidence.
2013-05-01 English
STOCK OPTION GRANT 03/21/2013
Director's Dealing
2013-04-01 English
STOCK OPTION GRANT 03/21/2013
Director's Dealing
2013-04-01 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.